Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and ...
Makary said the FDA is looking at prescription drugs like nausea medications and vaginal estrogen, and hopes to make changes ...
The Food and Drug Administration plans to drop its longtime standard of requiring two rigorous studies for new drug approvals ...
A system that allows drug makers to profit from restricted access will never liberalize on its own—and patients will continue ...
In a NEJM article, Commissioner Martin Makary and top deputy Vinay Prasad argued that the new policy should lower development costs and speed development without compromising agency standards.
Prasad and Makary disagree that some may believe this move shows the FDA relaxing its standards.
Drug sponsors should nevertheless bolster their application with “confirmative evidence,” chief regulators Marty Makary and Vinay Prasad said on Wednesday, including mechanistic data or findings from ...
Makary pointed to three bottlenecks: hospital contracting; ethical reviews and approvals; and the Investigational New Drug applications process ...
The FDA plans to adopt a new policy that will do away with the default requirement to base regulatory filings for new medicines on two pivotal trials, according to Commissioner Marty Makary.
FDA Commissioner Marty Makary says he believes "everything should be over the counter" unless a drug is unsafe, addictive or ...
Drugmakers are urging the FDA to reassess the regulatory process of switching medications from prescription to ...
The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for ...